COVID-19 has shined a spotlight on the cracks in pharmaceutical manufacturing. Even before the pandemic, life sciences experts had warned about the risks of a globally concentrated supply chain where pockets of raw materials and active pharmaceutical ingredient (API) suppliers in other regions of the world left pharma companies and patients particularly vulnerable to a sudden manufacturing stoppage. Any production disruptions, they said, could have catastrophic effects on human health. Their concerns were borne out with the sudden emergence of the novel coronavirus, which not only disrupted manufacturing but also led to widespread supply chain shortages as the pharma sector was focusing its attention on developing new therapeutics and vaccines for COVID-19. However, in an industry where companies make drugs that are life-saving, downtime is not an option. Technology that can make data actionable in real-time has been a boon to pharma companies during COVID-19. It has helped them keep employees healthy and safe, adjust to smaller teams and react to issues faster. But that technology should not be tucked away in a server closet once the pandemic subsides. It solves issues that pharma manufacturers can no longer ignore. Click Here For Complete Article Text
|
||||||||||||||||||
Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
|